Jan 20 (Reuters) – GSK will buy RAPT Therapeutics for $2.2 billion, the British drugmaker said on Tuesday, expanding its respiratory, immunology & inflammation offerings, led by the U.S. firm’s experimental drug for food allergies, ozureprubart.
The London-listed company will pay $58.00 per RAPT share, with an upfront investment of $1.9 billion, and the deal will give GSK global rights to the ozureprubart programme, excluding mainland China, Macau, Taiwan and Hong Kong.
The acquisition came as GSK said on Tuesday Japan’s Shionogi & Co would boost its stake in their ViiV Healthcare venture for HIV therapies after Pfizer’s exit. GSK retains its 78.3% majority stake in ViiV.
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Subhranshu Sahu)
